Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 684

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Prof Daniel Petrylak presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from a study looking at the use of the novel targeted treatment enfortumab vedotin in urotherial cancer.

The study enrolled urothelial patients who had been treated with platinum-based chemotherapy and/or checkpoint inhibitors.

A 44% response rate was seen and 12% had a complete response with no detectable sign of cancer.

Watch the interview here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation